share_log
Breakings ·  05:31
Foghorn Therapeutics Inc.: Cash, Cash Equivalents, and Marketable Securities of $267.4 Mln as of September 30, 2024, Provides Cash Runway Into 2027
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment